Growth • Exelixis
EXEL
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
17,5%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
13,3%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
10,2%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
11,5%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
14,2%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
5,8%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!